Literature DB >> 23590268

Comparison of 2011 and 2007 Global Initiative for Chronic Obstructive Lung Disease guidelines for predicting mortality and hospitalization.

Ane Johannessen1, Roy M Nilsen, Michael Storebø, Amund Gulsvik, Tomas Eagan, Per Bakke.   

Abstract

RATIONALE: The GOLD (Global Initiative for Chronic Obstructive Lung Disease) 2011 update on chronic obstructive pulmonary disease (COPD) bases disease classification on level of dyspnea, exacerbation history, and FEV1, whereas the previous GOLD categorized disease severity according to FEV1 only. Information on how the new classification predicts long-term hospitalizations and mortality is limited.
OBJECTIVES: To examine how GOLD 2011 predicts hospitalizations and mortality over an 8-year period and to assess differences in predictive ability between GOLD 2011 and GOLD 2007.
METHODS: In the GenKOLS study, 912 patients with COPD (FEV1/FVC < 0.7 and FEV1 < 80% predicted) aged 40 to 91 years were clinically examined. Patients answered questionnaires and performed lung function testing in 2003-2005. The population was followed for 8 years regarding hospitalizations (all-cause, respiratory) and mortality (all-cause, respiratory, cardiovascular). We performed logistic regression and receiver operating curve analyses for GOLD 2007 and GOLD 2011 with estimations of area under the curve (AUC) to compare the different classifications.
MEASUREMENTS AND MAIN RESULTS: Twenty percent of patients were classified as GOLD 2011 group A (mild), 30% as group B, 6% group as C, and 44% as group D (very severe). Patients in GOLD 2011 group D had odds ratios of 4.1 (95% confidence interval [CI], 2.5-6.7), 9.6 (95% CI, 3.4-27.0), and 3.0 (95% CI, 0.7-13.2) relative to group A for all-cause, respiratory, and cardiovascular mortality, respectively, and 3.8 (95% CI, 2.4-5.9) and 13.0 (95% CI, 6.6-25.6) for all-cause and respiratory hospitalizations, respectively. Associations were similar also for GOLD 2007. The adjusted AUC values for GOLD 2011 and GOLD 2007 were 0.82/0.82 for respiratory mortality (P = 0.87) and 0.77/0.76 for respiratory hospitalizations (P = 0.51).
CONCLUSIONS: The predictive ability of GOLD 2011 did not differ significantly from GOLD 2007 in terms of hospitalizations and mortality.

Entities:  

Mesh:

Year:  2013        PMID: 23590268     DOI: 10.1164/rccm.201212-2276OC

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  27 in total

1.  Six-minute-walk distance and accelerometry predict outcomes in chronic obstructive pulmonary disease independent of Global Initiative for Chronic Obstructive Lung Disease 2011 Group.

Authors:  Michael T Durheim; Patrick J Smith; Michael A Babyak; Stephanie K Mabe; Tereza Martinu; Karen E Welty-Wolf; Charles F Emery; Scott M Palmer; James A Blumenthal
Journal:  Ann Am Thorac Soc       Date:  2015-03

2.  Effect of Tiotropium on Outcomes in Patients With COPD, Categorized Using the New GOLD Grading System: Results of the UPLIFT® Randomized Controlled Trial.

Authors:  David M G Halpin; Donald P Tashkin; Bartolome R Celli; Inge Leimer; Norbert Metzdorf; Marc Decramer
Journal:  Chronic Obstr Pulm Dis       Date:  2015-06-23

3.  Quality of well-being outcomes in the National Emphysema Treatment Trial.

Authors:  Robert M Kaplan; Qiankun Sun; Andrew L Ries
Journal:  Chest       Date:  2015-02       Impact factor: 9.410

Review 4.  Update on management of stable chronic obstructive pulmonary disease.

Authors:  Ritwick Agrawal; Shahram Moghtader; Uma Ayyala; Venkata Bandi; Amir Sharafkhaneh
Journal:  J Thorac Dis       Date:  2019-09       Impact factor: 2.895

5.  Biobehavioral Prognostic Factors in Chronic Obstructive Pulmonary Disease: Results From the INSPIRE-II Trial.

Authors:  James A Blumenthal; Patrick J Smith; Michael Durheim; Stephanie Mabe; Charles F Emery; Tereza Martinu; Philip T Diaz; Michael Babyak; Karen Welty-Wolf; Scott Palmer
Journal:  Psychosom Med       Date:  2016 Feb-Mar       Impact factor: 4.312

6.  Association between frailty index, lung function, and major clinical determinants in chronic obstructive pulmonary disease.

Authors:  Simone Scarlata; Panaiotis Finamore; Alice Laudisio; Vittorio Cardaci; Mattia Ramaccia; Francesco D'Alessandro; Claudio Pedone; Raffaele Antonelli Incalzi; Matteo Cesari
Journal:  Aging Clin Exp Res       Date:  2021-05-19       Impact factor: 3.636

7.  Application of the new GOLD COPD staging system to a US primary care cohort, with comparison to physician and patient impressions of severity.

Authors:  Douglas W Mapel; Anand A Dalal; Phaedra T Johnson; Laura K Becker; Alyssa Goolsby Hunter
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2015-07-30

8.  Prevalence, risk factors, and health-related quality of life of osteoporosis in patients with COPD at a community hospital in Taiwan.

Authors:  Chun-Wei Lin; Yih-Yuan Chen; Yi-Jen Chen; Chi-Yen Liang; Ming-Shian Lin; Wei Chen
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2015-07-29

9.  Is asymptomatic peripheral arterial disease associated with walking endurance in patients with COPD?

Authors:  Kuo-Shao Sun; Ming-Shian Lin; Yi-Jen Chen; Yih-Yuan Chen; Solomon Chih-Cheng Chen; Wei Chen
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2015-07-29

10.  Finding the best thresholds of FEV1 and dyspnea to predict 5-year survival in COPD patients: the COCOMICS study.

Authors:  Pere Almagro; Pablo Martinez-Camblor; Joan B Soriano; Jose M Marin; Inmaculada Alfageme; Ciro Casanova; Cristobal Esteban; Juan J Soler-Cataluña; Juan P de-Torres; Bartolome R Celli; Marc Miravitlles
Journal:  PLoS One       Date:  2014-02-27       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.